Entospletinib

From WikiMD.org
Jump to navigation Jump to search

Entospletinib

Entospletinib (pronounced en-toh-spleh-tin-ib) is a selective inhibitor of the enzyme spleen tyrosine kinase (Syk). It is an experimental drug that is being studied for its potential use in the treatment of various types of cancer, including leukemia and lymphoma.

Etymology

The name "Entospletinib" is derived from the Greek word "entos", meaning "within", and "spleen", referring to the spleen tyrosine kinase that the drug targets. The "-ib" suffix is common in names of tyrosine kinase inhibitors.

Mechanism of Action

Entospletinib works by selectively inhibiting the activity of spleen tyrosine kinase, an enzyme that plays a crucial role in the signaling pathways of B cells and myeloid cells. By blocking this enzyme, Entospletinib can disrupt the growth and survival of cancer cells.

Clinical Trials

Entospletinib has been tested in several clinical trials for its potential use in treating various types of cancer. However, as of now, it has not been approved by the Food and Drug Administration (FDA) or any other regulatory authority.

Related Terms

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski